Most Serratia marcescens infections can be cured, but this bacterium is considerably harder to treat than many other common infections. S. marcescens carries built-in resistance to several antibiotic classes, and strains circulating in hospitals have been acquiring additional resistance genes at an alarming pace. The outcome depends heavily on where the infection takes hold, how sick the patient already is, and whether the right antibiotic is chosen early enough.
Who Gets These Infections
S. marcescens is an opportunistic pathogen, meaning it rarely causes disease in healthy people. Its primary targets are patients who are already critically ill, especially those in intensive care units or recovering from surgery where prolonged hospital stays and broad-spectrum antibiotic use are common.1PubMed Central. Serratia marcescens as an Uncommon Cause of Infection Following Craniectomy: A Case Report and Literature Review People with weakened immune systems, those on mechanical ventilation, and patients with indwelling catheters or other invasive devices are at the highest risk.
A retrospective study of 242 cases identified several independent risk factors for specific types of S. marcescens infection. Prior hospitalization roughly tripled the odds of bloodstream infection, while kidney disease quadrupled the odds of urinary tract infection. Patients who had previously been exposed to three or more classes of antibiotics were nearly four times as likely to develop a carbapenem-resistant infection, a particularly dangerous form.2PubMed Central. Epidemiology, resistance profiles, and risk factors of multidrug- and carbapenem-resistant Serratia marcescens infections: a retrospective study of 242 cases In practical terms, if you are a generally healthy person who develops a S. marcescens infection after, say, a minor wound, the prognosis is good. The real danger concentrates among hospitalized, debilitated patients.
Where in the Body S. marcescens Strikes
S. marcescens can infect almost any organ system, but it favors certain sites. A systematic review of invasive infections found that blood was the most common isolation site, accounting for about 45% of cases. Urine followed at around 14%, cerebrospinal fluid at 12%, and soft tissue at 10%. The organism also showed up in eye infections, wound infections, respiratory samples, bone, and even peritoneal fluid.3PubMed Central. Antimicrobial Treatment of Serratia marcescens Invasive Infections: Systematic Review An older study of S. marcescens bloodstream infections found a slightly different breakdown, with primary bacteremia dominant at 68%, pneumonia at 14%, and urinary tract infection at 9%.4PubMed. Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of the isolates
The site of infection matters enormously for curability. A urinary tract infection confined to the bladder is usually straightforward to treat, while meningitis or endocarditis caused by S. marcescens are far more dangerous and require longer, more aggressive antibiotic courses. Eye infections, though less common, can be devastating if not caught early, sometimes leading to loss of the eye even with treatment.
Why This Bacterium Is Harder to Treat
S. marcescens arrives at the fight with an unusually large arsenal of built-in defenses. Its high levels of antibiotic resistance stem from a combination of intrinsic, acquired, and adaptive mechanisms working together.5PubMed Central. Serratia marcescens antibiotic resistance mechanisms of an opportunistic pathogen: a literature review Most of the resistance genes sit on the chromosome itself rather than on transferable genetic elements, meaning every S. marcescens cell is born resistant to certain drugs regardless of prior antibiotic exposure.6Frontiers in Microbiology. The Genomic Basis of Intrinsic and Acquired Antibiotic Resistance in the Genus Serratia
Among the most clinically significant intrinsic defenses are resistance to polymyxins (a last-resort antibiotic class used against other resistant gram-negative bacteria) and natural resistance to many older penicillins and first-generation cephalosporins. The polymyxin resistance is encoded by a set of genes present in every strain, so colistin, which is a lifeline against many other multidrug-resistant organisms, simply does not work here.6Frontiers in Microbiology. The Genomic Basis of Intrinsic and Acquired Antibiotic Resistance in the Genus Serratia The bacterium also carries extensive efflux pump systems that actively pump antibiotics out of the cell before they can do their job.
The AmpC Factor
Like several related bacteria, S. marcescens carries a chromosomal gene for an enzyme called AmpC beta-lactamase, which can break down certain antibiotics. When this gene gets permanently switched on (a process called de-repression), resistance to drugs like ceftriaxone can develop during treatment. For years, clinicians worried that treating S. marcescens with ceftriaxone would trigger this resistance the same way it does in its close relative Enterobacter cloacae.
More recent research has been somewhat reassuring. The mutation rate for AmpC de-repression in S. marcescens turns out to be 50 to 150 times lower than in Enterobacter cloacae.7Journal of Antimicrobial Chemotherapy. Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase Laboratory experiments confirmed that even when the relevant genes are deleted in S. marcescens, the resulting resistance level is far lower than what happens in Enterobacter, and the bacterium does not survive at clinically relevant ceftriaxone concentrations. Current guidance now supports using ceftriaxone for S. marcescens infections when the isolate tests susceptible.8PubMed Central. Divergent genetic landscapes drive lower levels of AmpC induction and stable de-repression in Serratia marcescens compared to Enterobacter cloacae
Acquired Resistance and Carbapenemases
The bigger worry is what S. marcescens picks up from neighboring bacteria in hospital environments. Strains carrying carbapenem-destroying enzymes like KPC have been reported from hospitals in China, Greece, Brazil, and the United States, with many of these strains traced to surgical ICUs.5PubMed Central. Serratia marcescens antibiotic resistance mechanisms of an opportunistic pathogen: a literature review A recently described strain took this a step further, carrying two different carbapenemase genes (KPC-2 and NDM-1) on separate plasmids alongside its chromosomal resistance. Conjugation experiments showed that the NDM-1 plasmid could transfer to E. coli with no fitness cost, meaning it could spread easily between bacterial species.9PubMed Central. Emergence of carbapenem-resistant Serratia marcescens co-harboring blaNDM-1, blaKPC-2, and blaSRT-2 in bloodstream infection When carbapenems fail, the treatment options narrow dramatically, and these strains represent one of the most difficult-to-cure scenarios.
Which Antibiotics Work
For drug-susceptible S. marcescens, several effective options exist. Typical susceptibility patterns show resistance to amoxicillin-clavulanate and cefazolin (expected, given the intrinsic AmpC gene), but susceptibility to tobramycin, ceftriaxone, cefepime, carbapenems, and fluoroquinolones like levofloxacin.10Frontiers in Antibiotics. An Antimicrobial Treatment Assessment of Serratia marcescens Bacteremia and Endocarditis In a systematic review where susceptibility testing was available, amikacin stood out with no resistant isolates among those tested, while gentamicin resistance was low and cotrimoxazole resistance was considerably higher.3PubMed Central. Antimicrobial Treatment of Serratia marcescens Invasive Infections: Systematic Review
In practice, most clinicians start with a carbapenem or a fourth-generation cephalosporin like cefepime for serious infections, then narrow therapy once susceptibility results come back. The question of whether to use one antibiotic or two at the same time has been debated for decades. For nosocomial pneumonia broadly, most trials suggest monotherapy and combination therapy provide equivalent outcomes, though the sickest patients are typically excluded from these trials.11European Respiratory Review. Combination versus monotherapy for nosocomial pneumonia A study of bloodstream infections caused by cephalosporin-resistant gram-negative bacteria including S. marcescens found no significant survival benefit from combination therapy over monotherapy when appropriate antibiotics were selected.12International Journal of Antimicrobial Agents. Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species Getting the right antibiotic matters more than adding a second one.
Survival Rates and What Drives Them
Mortality from S. marcescens bloodstream infection is substantial but not insurmountable. A study of 98 episodes found a 28-day mortality of about 22%. The strongest predictors of death were low serum albumin (a marker of poor nutritional status) and a high organ failure score at the time the bacteremia was detected. Acquiring the infection in the ICU and having an indwelling urinary catheter also carried worse outcomes.13PubMed Central. Risk Factors for Mortality in Patients with Serratia marcescens Bacteremia The flip side of that 22% figure is that roughly four out of five patients with bloodstream infection survived, and many recovered fully.
For meningitis, a rarer but more feared complication, mortality was around 15%, with unfavorable outcomes linked to underlying brain tumors, ICU admission, and higher inflammatory markers at diagnosis.14Journal of Microbiology, Immunology and Infection. Serratia marcescens meningitis: Epidemiology, prognostic factors and treatment outcomes In both settings, the patients who died were generally sicker to begin with. The infection itself was the proximate cause, but the underlying condition heavily shaped whether the patient could survive long enough for antibiotics to work.
The Biofilm Problem
One reason S. marcescens infections can be stubborn is the organism’s ability to form biofilms, particularly on medical devices like urinary catheters. Bacteria embedded in biofilms are dramatically harder to kill than free-floating bacteria. Research on catheter-associated S. marcescens found that the antibiotic concentration needed to eliminate biofilm bacteria was far higher than the standard minimum inhibitory concentration measured in the lab.15Annals of Nigerian Medicine. Serratia marcescens in light of biofilm This mismatch means that standard susceptibility testing, the test clinicians rely on to pick antibiotics, may not accurately predict whether a drug will actually clear a device-related infection.
In practice, this often means the infected device has to come out. Removing a contaminated catheter, replacing a prosthetic joint component, or pulling an infected central line can be as important as the antibiotic itself. Cure rates for biofilm-associated infections are poor when the device stays in place, regardless of which antibiotic is used.
Phage Therapy and Experimental Approaches
With multidrug-resistant strains becoming more common, researchers have been exploring alternatives to conventional antibiotics. Bacteriophage therapy, which uses viruses that specifically infect and kill bacteria, has shown early promise against S. marcescens. A clinical application study tested a phage called Spe5P4 against a multidrug-resistant S. marcescens lung infection, and the results were encouraging: symptoms improved, imaging findings got better, and no adverse events were reported. The phage did not harm liver or kidney function, did not worsen antibiotic resistance, and did not increase the bacterial load.16PubMed Central. Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection
A more ambitious laboratory study tested a triple-combination approach, using phages, antibiotics at sub-inhibitory concentrations, and antimicrobial peptides together against multidrug-resistant S. marcescens biofilms. Phages plus antibiotics alone reduced biofilm mass but could not fully eradicate it. Adding the antimicrobial peptide cocktail eliminated over 99.99% of bacteria, whether they were free-floating or embedded in biofilms, with no regrowth observed.17PubMed Central. A Triple-Modality Peptide-Antibiotic-Phage Therapy Eradicates Multidrug-Resistant Serratia marcescens Biofilms These are still early-stage findings, far from standard clinical use, but they suggest that even the most resistant strains are not invulnerable when attacked from multiple angles simultaneously.
How Hospital Outbreaks Happen
S. marcescens has a well-documented tendency to cause hospital outbreaks, and understanding how these outbreaks unfold is part of understanding curability. If the source of ongoing transmission is not identified and eliminated, new infections keep appearing even as individual patients are treated.
The organism thrives in moist environments. Hospital sinks, drains, soap dispensers, and even cleaning equipment have all been implicated as reservoirs. In one ICU outbreak in Hungary, investigators found a strain resistant to quaternary ammonium disinfectants. Their analysis suggested the disinfectant-resistant bacteria were transferred from a contaminated sink into patient areas by the very cleaning equipment meant to prevent infections.18PubMed Central. Nosocomial outbreak caused by disinfectant-resistant Serratia marcescens in an adult intensive care unit, Hungary, February to March 2022 Another outbreak investigation traced carbapenem-resistant S. marcescens to a dirty utility room, a communal bathroom shared by ICUs, and the waste bucket of a dialysis system, with genetic testing confirming the patient and environmental isolates were the same strain.19PubMed. Hospital water environment and antibiotic use: key factors in a nosocomial outbreak of carbapenemase-producing Serratia marcescens
Controlling outbreaks requires a combination of contact isolation for infected or colonized patients, enhanced hand hygiene enforcement, environmental decontamination, and sometimes closing wards for deep cleaning.20International Journal of Hygiene and Environmental Health. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: Clinical aspects, risk factors and management The disinfectant resistance angle is troubling because it means standard cleaning protocols may not be enough for certain strains.
Neonates Face Special Risks
S. marcescens is a recurring nightmare in neonatal intensive care units. Newborns, especially premature infants, have immature immune systems and are often connected to multiple invasive devices. The bacterium causes a wide spectrum of illness in neonates ranging from asymptomatic colonization to full-blown sepsis and meningitis. Bloodstream infection is the most common presentation, followed by respiratory and gastrointestinal involvement, and outbreak strains are frequently multidrug-resistant.21PubMed Central. Serratia marcescens Infections in Neonatal Intensive Care Units (NICUs)
A documented NICU outbreak in Mexico illustrates the pattern. All 15 infected neonates had sepsis, and nearly all had invasive vascular access before becoming infected. Jaundice appeared in 80%, thrombocytopenia in 80%, and respiratory problems in two-thirds. One neonate, the index case, died on the fifth day of life. The outbreak was controlled only after hospital hygiene and sanitation measures were aggressively strengthened.22PubMed Central. Outbreak of Serratia marcescens in the Neonatal Intensive Care Unit of a Tertiary Care Hospital in Mexico A single death out of fifteen is a case fatality rate of about 7%, but the morbidity among survivors was severe, and this relatively low mortality likely reflects the susceptibility of the strain to available antibiotics. Outbreaks involving resistant strains can be much worse.
Faster Diagnosis as Part of the Cure
One underappreciated part of curing S. marcescens infections is identifying them quickly. Standard blood cultures can take 24 to 48 hours or longer to grow and identify the organism, and additional time is needed for susceptibility testing. During that wait, patients are often on empiric antibiotics that may not cover S. marcescens adequately, given its unusual resistance profile. A real-time PCR assay has been developed that can detect S. marcescens in blood at low concentrations and simultaneously flag the presence of carbapenem resistance genes.23FEMS Microbiology Letters. Rapid and quantitative detection of blood Serratia marcescens by a real-time PCR assay: Its clinical application and evaluation in a mouse infection model Faster identification means clinicians can switch to the right antibiotic sooner, and earlier appropriate therapy is one of the strongest predictors of survival in serious bacterial infections.
The Curious Role of Prodigiosin
S. marcescens is famous for producing a red pigment called prodigiosin, the substance behind the dramatic pink stains it leaves on bathroom tiles and shower curtains. This pigment is more than cosmetic. Research shows that prodigiosin production is linked to enhanced energy metabolism and increased biomass, giving pigmented strains a growth advantage under certain conditions.24PubMed Central. Prodigiosin pigment of Serratia marcescens is associated with increased biomass production Intriguingly, when S. marcescens is infected by a bacteriophage, pigment production can increase dramatically, with one experiment showing a fivefold jump in pigment concentration after phage exposure during stationary phase.25Scientific Reports. Serratia marcescens ATCC 274 increases production of the red pigment prodigiosin in response to Chi phage infection
Prodigiosin itself has drawn interest as a potential anticancer and antimicrobial compound in laboratory studies, though none of this has translated to clinical treatments yet. For the purposes of curing S. marcescens infections, the pigment is mainly relevant as a diagnostic clue. Colonies that appear red or pink on agar plates immediately suggest S. marcescens, speeding identification. However, not all clinical strains produce visible pigment, so its absence does not rule out the organism.
A Pathogen Once Thought Harmless
Part of the reason S. marcescens became so entrenched in hospital settings is that it was long considered completely harmless. The U.S. military even used it as a simulant in biological warfare experiments during the Cold War, releasing it over populated areas including San Francisco to study how airborne bacteria would disperse. The assumption was that the red-pigmented organism posed no risk to human health. That assumption was wrong, and the experiments were exposed by the press in the 1970s, leading to congressional hearings. By the mid-1960s, S. marcescens had been established as a definite human pathogen.26PubMed Central. Serratia infections: from military experiments to current practice The decades of treating it as benign allowed it to become well established in healthcare environments before anyone thought to control it, and hospitals have been dealing with the consequences ever since.